Minimal Side Effects with New Class of Breast Cancer Drugs
Why CDK inhibitors?
Because HR+ metastatic breast cancers are by far the most common form of breast cancer, there has been a lot of excitement over CDK inhibitors. Aditya Bardia, senior author on the article posted in The Oncologist, and breast cancer specialist at the Massachusetts General Hospital Cancer Center in Boston, wrote that “CDK inhibitors has changed the landscape of management of HR+ breast cancer.” Combined with the drugs’ individual recognitions as breakthroughs in the treatment of breast cancer, breast cancer patients can be hopeful for effective treatment with fewer consequences in the near future.
